Antidiabetics Market Demand to Hit USD 130B by 2026: Global Market Insights, Inc.

SELBYVILLE, Del., June 17, 2020 /PRNewswire/ -- Global Market Insights, Inc. has recently added a new report on the antidiabetics market, which estimates the market valuation for antidiabetics will cross US $130 billion by 2026. The rising prevalence of obesity and growing geriatric population among several other severe health conditions will act as a key driver for the antidiabetics industry. According to the World Health Organization (WHO), nearly 1.6 million deaths in the world are attributed to diabetes alone. Moreover, about 422 million people suffer from diabetes globally. Therefore, to offer better treatment and to reduce mortality rate, the antidiabetics market will witness lucrative growth in the future.

Recently, the outbreak of COVID-19 has affected diabetic patients in a more challenging manner, leading to a rise in antidiabetic products worldwide. Also, a growing geriatric pool and increasing obese population will offer positive growth to the industry. Therefore, major market players operating in the antidiabetic market will foresee immense growth opportunities in the forecast period.

Request a sample of this research report at https://www.gminsights.com/request-sample/detail/504

The insulin segment held the largest revenue share in 2019 and is estimated to progress at more than a 12% CAGR during 2020 to 2026. An increasing number of patients suffering from type 2 diabetes and adoption of advanced treatment methods for better outcomes will increase its preference among customers. Moreover, rising investment by industry players for research and development of new products will influence the segment growth.

The geriatric population accounted for around 40.0% of the market share in 2019 and is poised to grow at a substantial rate by 2026. According to the Centers for Disease Control and Prevention, more than 25% of the U.S. population aged above 65 years suffer from diabetes. Therefore, increasing diabetes in the geriatric population will accelerate the segmental growth. Furthermore, growing government initiatives through awareness programs will influence the segmental growth.

The intravenous infusions segment is projected to proceed at about a 11.3% CAGR during 2020 to 2026. The advantages of intravenous infusions are associated with higher concentration of medication delivery into the body more effectively. Such benefits will increase its preference among customers. Thus, the increasing diabetic population and adoption of advanced methods will positively impact the segment size.

Browse key industry insights spread across 202 pages with 266 market data tables and 10 figures and charts from the report, "Antidiabetics Market Share & Forecast, 2020 - 2026" in detail, along with the table of contents:

https://www.gminsights.com/industry-analysis/antidiabetics-market

Europe's antidiabetic market constituted about more than 32% of the market share in 2019. The growing geriatric population and rising cases of diabetic patients in the region will provide growth opportunities to the market. Moreover, entry of major market players to set their footprint in this industry will further augment the market growth. Furthermore, rising government funding in research and development will further stimulate Europe's antidiabetic drugs market growth during the forecast years.

Some major findings of the antidiabetics market report include:

• Increasing prevalence of COVID-19 in diabetic patients will drive the market growth.
• Rising R&D expenditure aimed at new product development and strong product pipeline will boost the market growth.
• Growing government initiatives and increasing healthcare expenditure will have a positive impact on the market demand.

Major players operating in the antidiabetics industry share include Novo Nordisk, AstraZeneca, Bayer Corporation, Boehringer Ingelheim, Bristol-Myers Squibb, among other players

Industry players operating in the antidiabetics market are implementing various strategies such as new product development, collaborations, and partnerships to gain a competitive advantage for business expansion. For instance, in June 2017, Merck and Pfizer announced two Phase 3 studies of ertugliflozin, an investigational oral SGLT-2 inhibitor. The drug was developed to improve glycemic control of patients suffering with type 2 diabetes. This product strategy strengthened the firm's business position along with its brand image in the market.

Browse complete report table of contents at https://www.gminsights.com/toc/detail/antidiabetics-market

Partial chapters of report table of contents (TOC):

Chapter 2. Executive Summary

2.1. Antidiabetics industry 360° synopsis, 2015 - 2026

2.1.1. Business trends

2.1.2. Product trends

2.1.3. Patient population trends

2.1.4. Route of administration trends

2.1.5. Regional trends

Chapter 3. Antidiabetics Industry Insights

3.1. Industry segmentation

3.2. Industry landscape, 2015 - 2026

3.3. Industry impact forces

3.3.1. Growth drivers

3.3.1.1. Strong product pipeline of antidiabetics

3.3.1.2. Globally rising prevalence of diabetes

3.3.1.3. Increasing prevalence of lifestyle induced disorders such as obesity

3.3.1.4. Growing adoption of oral antidiabetic drugs

3.3.1.5. Rising spending on R&D for innovative drugs

3.3.2. Industry pitfalls and challenges

3.3.2.1. Prohibitive cost of insulin

3.3.2.2. Safety issues pertaining to some diabetic drugs

3.4. Regulatory landscape

3.4.1. U.S.

3.4.2. Europe

3.5. Clinical workflow analysis

3.6. Reimbursement scenario

3.6.1. U.S.

3.6.2. Europe

3.6.3. Australia

3.7. Growth potential analysis

3.7.1. By product

3.7.2. By patient population

3.7.3. By route of administration

3.8. COVID-19 impact analysis

3.9. Porter's analysis

3.10. Competitive landscape, 2019

3.11. PESTEL analysis

Browse related report:

Diabetes Care Devices Market Size By Products (Blood Glucose Monitoring Devices {Self-Monitoring Blood Glucose Meters, Continuous Glucose Monitors, Testing Strips, Lancets}, Insulin Delivery Devices {Insulin Pumps [Tubed Pumps, Tubeless Pumps], Pen [Reusable, Disposable], Pen Needles [Standard, Safety], Syringes}), By End-Use (Hospitals, Ambulatory Surgery Centers, Diagnostic Centers, Home Care) Industry Analysis Report, Regional Outlook, Application Potential, Price Trends, Competitive Market Share & Forecast, 2019 - 2025

https://www.gminsights.com/industry-analysis/diabetes-care-devices-market

About Global Market Insights

Global Market Insights, Inc., headquartered in Delaware, U.S., is a global market research and consulting service provider; offering syndicated and custom research reports along with growth consulting services. Our business intelligence and industry research reports offer clients with penetrative insights and actionable market data specially designed and presented to aid strategic decision making. These exhaustive reports are designed via a proprietary research methodology and are available for key industries such as chemicals, advanced materials, technology, renewable energy and biotechnology.

Contact Us:

Arun Hegde
Corporate Sales, USA
Global Market Insights, Inc.
Phone: 1-302-846-7766
Toll Free: 1-888-689-0688
Email: [email protected]

Related Images

antidiabetics-market-size-worth.png
Antidiabetics Market size worth around $130B by 2026
Antidiabetics Market size is predicted to surpass USD 130 billion in 2026, according to a new research report by Global Market Insights, Inc.

Related Links

Tubeless Insulin Pump Market

Pet Diabetes Care Devices Market

SOURCE Global Market Insights, Inc.